ZRANB1 Is an EZH2 Deubiquitinase and a Potential Therapeutic Target in Breast Cancer

Although EZH2 enzymatic inhibitors have shown anti-tumor effects in EZH2-mutated lymphoma and ARID1A-mutated ovarian cancer, many cancers do not respond because EZH2 can promote cancer independently of its histone methyltransferase activity. Here we identify ZRANB1 as the EZH2 deubiquitinase. ZRANB1...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:Cell Rep
Auteurs principaux: Zhang, Peijing, Xiao, Zhenna, Wang, Shouyu, Zhang, Mutian, Wei, Yongkun, Hang, Qinglei, Kim, Jongchan, Yao, Fan, Rodriguez-Aguayo, Cristian, Ton, Baochau N., Lee, Minjung, Wang, Yumeng, Zhou, Zhicheng, Zeng, Liyong, Hu, Xiaoyu, Lawhon, Sarah E., Siverly, Ashley N., Su, Xiaohua, Li, Jia, Xie, Xiaoping, Cheng, Xuhong, Liu, Liang-Chiu, Chang, Hui-Wen, Chiang, Shu-Fen, Lopez-Berestein, Gabriel, Sood, Anil K., Chen, Junjie, You, M. James, Sun, Shao-Cong, Liang, Han, Huang, Yun, Yang, Xianbin, Sun, Deqiang, Sun, Yutong, Hung, Mien-Chie, Ma, Li
Format: Artigo
Langue:Inglês
Publié: 2018
Sujets:
Article
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC5933875/
https://ncbi.nlm.nih.gov/pubmed/29669287
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.celrep.2018.03.078
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires